2246 - Clinical Study of Hypofractionated Radiotherapy Combined with Temozolomide and Bevacizumab In the Treatment of Newly Diagnosed Postoperative Glioblastoma

03:00pm - 04:00pm ET

Poster Hall - Exhibit Hall A

Screen: 12

POSTER

Presenter(s)

Can Wang, MD, PhD - Chongqing University Cancer Hospital, Shapingba, Chongqing

C. Wang¹, H. Tu¹, C. B. Fan², Z. Tang¹, Q. Luo¹, and Y. Luo¹; ¹Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China, ²Department of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China

Purpose/Objective(s): To evaluate the efficacy and safety of hypofractionated radiotherapy combined with temozolomide and bevacizumab in patients with newly diagnosed postoperative glioblastoma.

Materials/Methods: A total of 48 postoperative glioblastoma patients treated at Chongqing University Cancer Hospital from Jan. 2020 to Dec. 2023 were enrolled and divided into two groups. The study group received hypofractionated radiotherapy (60Gy/20F) in combination with temozolomide and bevacizumab, while the control group received radiotherapy (60Gy/30F) with temozolomide alone. In the study group, bevacizumab (7.5mg/kg) was administered every two weeks, starting one week before radiotherapy and continuing concurrently with hypofractionated radiotherapy and temozolomide. In the control group, radiotherapy was administered concurrently with temozolomide. After radiotherapy, the study group received temozolomide plus bevacizumab for six cycles, while the control group received temozolomide alone for six cycles. Treatment in both groups was continued until disease progression or intolerable toxicity. Clinical efficacy was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria.

Results: The study group had significantly higher objective response rate (ORR, 54.17% vs 37.50%) and disease control rate (DCR, 91.67% vs 79.17%) than the control group (all P < 0.05). Median overall survival (OS) was 18.2 months (95% CI: 8.2-12.4) in the study group and 12.4 months (95% CI: 5.8-9.6) in the control group. Median progression-free survival (PFS) was 13.2 months (95% CI: 6.4-10.2) in the study group and 8.9 months (95% CI: 3.8-7.2) in the control group. The overall incidence of adverse reactions was 50.00% in both groups, with no significant difference (P > 0.05).

Conclusion: Hypofractionated radiotherapy combined with temozolomide and bevacizumab significantly improves PFS, OS, ORR and DCR in patients with newly diagnosed postoperative glioblastoma, with a comparable safety profile to conventional radiotherapy.